drugset / Trial / NCT02810223
Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, multi-center study to determine the efficacy and safety of an experimental therapy called CART-19 in patients with chemo-refractory and relapsed B-cell ALL.
Timeline
- Start
- 2016-05
- Primary completion
- 2017-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tisagenlecleucel | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | Tisagenlecleucel | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | Tisagenlecleucel | Cell therapy | 2.5e+08 cells | Intravenous |